"The company says that their research will not solely focus on creating new molecules, but will try to develop new formulations that are easier to adhere to, including paediatric fixed-dose combinations.
"Dominique Limet, the new chief executive, told Reuters that 'Our intent is to look at what we can do with the portfolio we get from Pfizer and Glaxo to build new combinations which will completely transform the way we treat HIV.'
"The company also states that it is committed to broadening access to medicines around the world and maintaining GSK’s Positive Action programme, which supports community projects."
Read more in Aidsmap, November 3, 2009.
0 comments:
Post a Comment